Engineering small-molecule analogues of altiratinib via CREB-regulated transcription co-activator 3-target screening for the development of potent and safe topical therapeutics against skin hyperpigmentary diseases

Affiliations

• ¹ Department of Dermatology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.
• ² College of Pharmacy and Institute of Pharmaceutical Sciences, CHA University, Pocheon, South Korea.
• ³ New Drug Development Center (NDDC), Daegu-Gyeongbuk Medical Innovation Foundation (DGMIF), Daegu, South Korea.
• ⁴ Department of Brain Science, Brain Korea 21 project, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.